Maria Bencivenga
A5001941833- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Esophageal Cancer Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Esophageal and GI Pathology
- Helicobacter pylori-related gastroenterology studies
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer-related gene regulation
- Cancer Genomics and Diagnostics
- Enhanced Recovery After Surgery
- Lung Cancer Diagnosis and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Cancer Research and Treatments
- RNA modifications and cancer
- Colorectal Cancer Surgical Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cardiac, Anesthesia and Surgical Outcomes
- Multiple and Secondary Primary Cancers
- Bariatric Surgery and Outcomes
- Cancer Cells and Metastasis
- Molecular Biology Techniques and Applications
University of Verona
2016-2025
Azienda Ospedaliera Universitaria Integrata Verona
2015-2024
National University of Singapore
2024
Hospital de Niños de la Santísima Trinidad
2020
Provincia Autonoma di Trento
2015-2019
Creative Research Enterprises (United States)
2016
Danylo Halytsky Lviv National Medical University
2016
University of Naples Federico II
2009
The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD).
Abstract Gastric cancer is the world's third leading cause of mortality. In spite significant therapeutic improvements, clinical outcome for patients with advanced gastric poor; thus, identification and validation novel targets extremely important from a point view. We generated wide, multilevel platform models, comprising 100 patient-derived xenografts (PDX), primary cell lines, organoids. Samples were classified according to their histology, microsatellite stability, Epstein–Barr virus...
Abstract Background Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but general agreement on managing oligometastatic disease has yet be achieved. An international multi-disciplinary workshop was held Bertinoro, Italy, November 2022 verify whether achieving consensus at...
This article is about an emerging issue in esophageal surgery: enhanced recovery after surgery (ERAS) Few data are published literature and its safety feasibility still debated. The focus of our paper on the ERAS protocol for esophagectomy (including both Ivor–Lewis McKeown procedure) a high volume center comparing to standard perioperative protocol. We introduced novelty item this type resume oral feeding first postoperative day. analyzed dropout rate each morbidity. studied 39 patients...
Peritoneal carcinomatosis is the most frequent site of metastases in patients with gastric cancer. Current standard treatment palliative systemic chemotherapy very poor prognosis. Cytoreductive surgery (CRS) combined hyperthermic intraperitoneal (HIPEC) resulted long-term benefits selected patients. Among peritoneal carcinomatosis, a distinctive subset oligometastatic disease which characterized by low metastatic burden. Pressurized aerosol (PIPAC) recent technique used combination promising...
Background: Prognosis of patients affected by metastatic esophageal–gastric junction (EGJ) or gastric cancer (GC) remains dismal. Trastuzumab, an anti-HER2 monoclonal antibody, is the only targeted agent approved for first-line treatment with HER2-overexpressing advanced EGJ GC in combination chemotherapy. However, invariably become resistant during this treatment. We recently identified overexpression fibroblast growth factor (FGF) receptor 3 (FGFR3) as a molecular mechanism responsible...
Abstract Background This study evaluated the efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic as a bidirectional approach for gastric cancer (GC) patients synchronous peritoneal metastases (SPM). Methods A retrospective analysis prospective PIPAC database was queried who underwent between October 2019 and April 2022 at two high-volume GC surgery units in Italy (Verona Siena). Surgical oncological outcomes were analyzed. Results Between 2022, 74 procedures 42...
The association between each Enhanced Recovery After Surgery (ERAS) component and the incidence of major postoperative complications following Ivor Lewis or McKeown surgery is understudied. Therefore, we wanted to determine ERAS components, complications, reasons for non-compliance with program. Data were extracted from prospective Registry managed by University Verona, Italy. We searched compared data (Clavien-Dindo Classification ≥3B) 15 items in patients undergoing radical intent...
Evidence regarding staging laparoscopy(SL)for clinical metastatic(cM+)gastric cancer(GC)patients is limited. Recently,Italian Gastric Cancer Research Group(GIRCG)study showed SL changed peritoneal status in over 20% of cases. This study aims to evaluate SL's role cM+ patients and refine indications. Data GC who underwent between 2010 2022 at nine GIRCG Centers were retrospectively analyzed.Primary outcome was yield,defined as by SL,over all SLs. Among 182 received SL,38(20.9%)had SL-findings...
Abstract Background To reduce the clinical and economic burden of complications after gastrectomy for gastric cancer, specific should be targeted to effectively allocate healthcare resources quality improvement preventive measures. The aim this study was assess impact on outcomes. Methods This a retrospective multicentre patients who underwent (sub)total or junctional adenocarcinoma at 43 centres in 16 countries between 2017 2021. Outcomes were escalation care, reoperation, prolonged...